VEGFA and cancer: Clinically, development of antibodies targeting VEGF as well as kinase inhibitors targeting VEGFR2 have been effective in controlling pathological angiogenesis in diseases characterized by abnormal angiogenesis such as age related macular degeneration, diabetes induced macular edema, and cancer (Rosenfeld et al., 2006; Tah et al., 2015; Ferrara and Adamis, 2016).